Login / Signup

The fragility of randomized placebo-controlled trials for irritable bowel syndrome.

MaryJane O WilliamsMary SedarousBrittany DennisVanessa DlaminiObioma NwaiwuLinda A NguyenPhilip N Okafor
Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2022)
A median of six participants is needed to nullify results in the included IBS trials suggesting how easily statistical significance based on a threshold p-value may be overturned.
Keyphrases
  • irritable bowel syndrome
  • placebo controlled
  • double blind
  • phase iii
  • phase ii
  • clinical trial
  • study protocol
  • phase ii study
  • randomized controlled trial
  • squamous cell carcinoma
  • rectal cancer